Company Participation - Galectin Therapeutics, Inc. will participate in the H.C. Wainwright 27 Annual Global Investment Conference from September 8-10, 2025 in New York, NY [1] - The company presentation is scheduled for September 8, 2025, at 1:00 PM ET, with a live and archived webcast available [2] Management Availability - The management team, including CEO Joel Lewis and CMO Khurram Jamil, will be available for one-on-one meetings during the conference [3] Company Overview - Galectin Therapeutics focuses on developing novel therapies for chronic liver disease and cancer, with its lead drug belapectin targeting the galectin-3 protein [4] - Belapectin has received Fast Track designation from the U.S. FDA and is primarily being developed for metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis [4] - The company is also exploring treatments for advanced head and neck cancers and other malignancies, with further development dependent on finding suitable partners [4]

Core Insights - Galectin Therapeutics Inc. is set to present data from its NAVIGATE study on belapectin, a galectin-3 inhibitor, at the EASL 2025 meeting, highlighting its significance in the hepatology community [1][2] - The NAVIGATE study focuses on patients with MASH cirrhosis and portal hypertension, conditions that have been historically overlooked despite their severe impact on patients [2] - The company is also analyzing biomarker data from the NAVIGATE study, with additional results expected to be shared in the second quarter of 2025 [2] Company Overview - Galectin Therapeutics is dedicated to developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3, which is involved in various inflammatory and fibrotic diseases [3] - Belapectin has received Fast Track designation from the U.S. FDA and is primarily focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, representing a significant drug development opportunity [3] - The company is also exploring additional development programs in cancer immunotherapy, contingent on finding suitable partnerships for efficient development [3]